Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM8969, an orally available NLRP3 inhibitor as pre-clinical candidate. (IMAGE)

InSilico Medicine

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM8969, an orally available NLRP3 inhibitor as pre-clinical candidate.

Caption

Powered by Insilico’s proprietary Pharma.AI platform, the BBB (blood-brain barrier) penetrable molecule was designed as a potential treatment of various inflammation-related diseases, including gout flare, asthma, Crohn’s disease, Alzheimer’s disease and epilepsy.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.